Back to Search
Start Over
CanariaBio Inc Announces Enrollment Completion of randomized Phase 2 study of Oregovomab in combination with chemotherapy as neo-adjuvant treatment of patients with Advanced Ovarian Cancer
- Source :
- PR Newswire. August 23, 2024
- Publication Year :
- 2024
-
Abstract
- SEOUL, South Korea, Aug. 23, 2024 /PRNewswire/ -- CanariaBio Inc, a leading late-stage biotechnology company, announces the successful completion of enrollment of 88 patients in a randomized Phase 2 study [...]
Details
- Language :
- English
- Database :
- Gale General OneFile
- Journal :
- PR Newswire
- Publication Type :
- News
- Accession number :
- edsgcl.805807461